NO20006667L - Retinoid-relaterte reseptor funksjonsregulerende middel - Google Patents

Retinoid-relaterte reseptor funksjonsregulerende middel

Info

Publication number: NO20006667L
Authority: NO; Norway
Prior art keywords: cachexia; hydrocarbon group; insulin; hydrogen; optionally substituted
Prior art date: 1998-07-01

Application number

NO20006667A

Other languages

English (en)

Norwegian (no)

Other versions

NO20006667D0 (no

Inventor

Yasuo Sugiyama

Yu Momose

Hiroyuki Kimura

Junichi Sakamoto

Hiroyuki Odaka

Original Assignee

Takeda Chemical Industries Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-01

Filing date

2000-12-27

Publication date

2001-02-28

2000-12-27 Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd

2000-12-27 Publication of NO20006667D0 publication Critical patent/NO20006667D0/no

2001-02-28 Publication of NO20006667L publication Critical patent/NO20006667L/no

Links

150000004492 retinoid derivatives Chemical class 0.000 title 1
206010006895 Cachexia Diseases 0.000 abstract 8
229910052739 hydrogen Inorganic materials 0.000 abstract 4
239000001257 hydrogen Substances 0.000 abstract 4
208000011580 syndromic disease Diseases 0.000 abstract 4
208000002705 Glucose Intolerance Diseases 0.000 abstract 3
206010012601 diabetes mellitus Diseases 0.000 abstract 3
125000001183 hydrocarbyl group Chemical group 0.000 abstract 3
201000009104 prediabetes syndrome Diseases 0.000 abstract 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
206010022489 Insulin Resistance Diseases 0.000 abstract 2
125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 2
125000002029 aromatic hydrocarbon group Chemical group 0.000 abstract 2
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
208000017169 kidney disease Diseases 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
206010002383 Angina Pectoris Diseases 0.000 abstract 1
201000001320 Atherosclerosis Diseases 0.000 abstract 1
206010006187 Breast cancer Diseases 0.000 abstract 1
208000026310 Breast neoplasm Diseases 0.000 abstract 1
208000002177 Cataract Diseases 0.000 abstract 1
208000002249 Diabetes Complications Diseases 0.000 abstract 1
206010012655 Diabetic complications Diseases 0.000 abstract 1
208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
206010060378 Hyperinsulinaemia Diseases 0.000 abstract 1
208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
206010020772 Hypertension Diseases 0.000 abstract 1
206010062016 Immunosuppression Diseases 0.000 abstract 1
102000004877 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
206010054805 Macroangiopathy Diseases 0.000 abstract 1
208000029725 Metabolic bone disease Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
206010049088 Osteopenia Diseases 0.000 abstract 1
208000001132 Osteoporosis Diseases 0.000 abstract 1
206010060862 Prostate cancer Diseases 0.000 abstract 1
208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
208000017442 Retinal disease Diseases 0.000 abstract 1
206010038923 Retinopathy Diseases 0.000 abstract 1
208000020764 Sensation disease Diseases 0.000 abstract 1
208000000453 Skin Neoplasms Diseases 0.000 abstract 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
230000036528 appetite Effects 0.000 abstract 1
235000019789 appetite Nutrition 0.000 abstract 1
206010008118 cerebral infarction Diseases 0.000 abstract 1
208000026106 cerebrovascular disease Diseases 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003623 enhancer Substances 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
230000037406 food intake Effects 0.000 abstract 1
235000012631 food intake Nutrition 0.000 abstract 1
208000004104 gestational diabetes Diseases 0.000 abstract 1
230000003451 hyperinsulinaemic effect Effects 0.000 abstract 1
201000008980 hyperinsulinism Diseases 0.000 abstract 1
230000001631 hypertensive effect Effects 0.000 abstract 1
230000001506 immunosuppresive effect Effects 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
230000002458 infectious effect Effects 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
208000032839 leukemia Diseases 0.000 abstract 1
201000006938 muscular dystrophy Diseases 0.000 abstract 1
208000010125 myocardial infarction Diseases 0.000 abstract 1
201000009925 nephrosclerosis Diseases 0.000 abstract 1
201000001119 neuropathy Diseases 0.000 abstract 1
230000007823 neuropathy Effects 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
208000033808 peripheral neuropathy Diseases 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
201000000849 skin cancer Diseases 0.000 abstract 1
125000000547 substituted alkyl group Chemical group 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1
230000001988 toxicity Effects 0.000 abstract 1
231100000419 toxicity Toxicity 0.000 abstract 1
230000007704 transition Effects 0.000 abstract 1
201000008827 tuberculosis Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Hematology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)

NO20006667A 1998-07-01 2000-12-27 Retinoid-relaterte reseptor funksjonsregulerende middel NO20006667L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP18669898		1998-07-01
PCT/JP1999/003520 WO2000001679A1 (fr)	1998-07-01	1999-06-30	Regulateurs du recepteur associe aux retinoides

Publications (2)

Publication Number	Publication Date
NO20006667D0 NO20006667D0 (no)	2000-12-27
NO20006667L true NO20006667L (no)	2001-02-28

Family

ID=16193077

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20006667A NO20006667L (no)	1998-07-01	2000-12-27	Retinoid-relaterte reseptor funksjonsregulerende middel

Country Status (16)

Country	Link
US (1)	US6545009B1 (fr)
EP (1)	EP1092711A4 (fr)
KR (1)	KR20010053282A (fr)
CN (1)	CN1314899A (fr)
AU (1)	AU4394799A (fr)
BR (1)	BR9911752A (fr)
CA (1)	CA2332178A1 (fr)
HU (1)	HUP0102470A3 (fr)
ID (1)	ID29247A (fr)
IL (1)	IL140422A0 (fr)
LV (1)	LV12633B (fr)
NO (1)	NO20006667L (fr)
PL (1)	PL345247A1 (fr)
SK (1)	SK20182000A3 (fr)
WO (1)	WO2000001679A1 (fr)
ZA (1)	ZA200007635B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6548529B1 (en)	1999-04-05	2003-04-15	Bristol-Myers Squibb Company	Heterocyclic containing biphenyl aP2 inhibitors and method
AR035016A1 (es)	1999-08-25	2004-04-14	Takeda Chemical Industries Ltd	Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
WO2002076959A1 (fr) *	2001-03-23	2002-10-03	Takeda Chemical Industries, Ltd.	Derive heterocyclique a cinq membres d'acide alcanoique
MXPA03009562A (es) *	2001-04-18	2004-02-12	Genzyme Corp	METODO PARA TRATAR EL SiNDROME X CON POLIAMINAS ALIFATICAS.
GB0112348D0 (en) *	2001-05-19	2001-07-11	Smithkline Beecham Plc	Compounds
WO2003000301A1 (fr) *	2001-06-22	2003-01-03	Merck & Co., Inc.	Combinaison d'un ligand de ppar-alpha et d'un glucocorticoide pour le traitement ou la prevention d'une inflammation
JP2003081832A (ja) *	2001-06-26	2003-03-19	Takeda Chem Ind Ltd	レチノイド関連受容体機能調節剤
EP1405636A4 (fr) *	2001-06-26	2009-04-15	Takeda Pharmaceutical	Regulateur de la fonction du recepteur relatif aux retinoides
DE60217918T2 (de) *	2001-12-29	2007-11-15	Novo Nordisk A/S	Kombinierte verwendung einer glp-1-verbindung und eines aldose reduktase inhibitors
US7183276B2 (en)	2002-02-28	2007-02-27	Takeda Pharmaceutical Company Limited	Azole compounds
PL376733A1 (pl)	2002-11-01	2006-01-09	Takeda Pharmaceutical Company Limited	Środek do zapobiegania lub leczenia neuropatii
GB0303503D0 (en) *	2003-02-14	2003-03-19	Novartis Ag	Organic compounds
DE10308353A1 (de) *	2003-02-27	2004-12-02	Aventis Pharma Deutschland Gmbh	Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2599281C (fr) *	2005-02-25	2012-01-17	Heonjoong Kang	Derives de thiazole utilises comme ligands ppar delta et processus de fabrication de ceux-ci
KR100797798B1 (ko) *	2005-02-25	2008-01-24	재단법인서울대학교산학협력재단	퍼록시솜 증식자 활성화 수용체 델타 리간드 티아졸 유도체및 그의 제조방법
JPWO2007043401A1 (ja) *	2005-10-07	2009-04-16	キッセイ薬品工業株式会社	含窒素複素環化合物およびそれを含有する医薬組成物
WO2008064136A2 (fr) *	2006-11-17	2008-05-29	Acadia Pharmaceuticals Inc.	Composés présentant une activité au niveau des récepteurs d'acide rétinoïque
JP5461197B2 (ja)	2007-02-02	2014-04-02	ベイラーカレッジオブメディスン	代謝障害を処置するための組成物および方法
US9085566B2 (en)	2007-02-02	2015-07-21	Baylor College Of Medicine	Compositions and methods for the treatment of metabolic and related disorders
US9187485B2 (en)	2007-02-02	2015-11-17	Baylor College Of Medicine	Methods and compositions for the treatment of cancer and related hyperproliferative disorders
US9212179B2 (en)	2007-02-02	2015-12-15	Baylor College Of Medicine	Compositions and methods for the treatment of metabolic disorders
US9233941B2 (en)	2007-02-02	2016-01-12	Baylor College Of Medicine	Methods and compositions for the treatment of body weight related disorders
TWI558320B (zh)	2007-08-13	2016-11-21	孟山都科技有限責任公司	控制植物寄生性線蟲的化合物及方法以及被覆有該化合物之種子
US20120244079A1 (en) *	2009-05-07	2012-09-27	Baylor College Of Medicine	Traceable retinoid acid for imaging, disease prevention and therapy
GB0915196D0 (en)	2009-09-01	2009-10-07	King S College London	Therapeutic compounds and their use
WO2012028100A1 (fr) *	2010-09-01	2012-03-08	Glaxo Group Limited	Nouveaux composés
AU2015365738B2 (en) *	2014-12-19	2020-07-23	Galderma Research & Development	Novel compounds, synthesis method thereof and use of same in medicine and in cosmetics
WO2018002673A1 (fr)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii
US10865793B2 (en)	2016-12-06	2020-12-15	Air Squared, Inc.	Scroll type device having liquid cooling through idler shafts
US20200025199A1 (en)	2018-07-17	2020-01-23	Air Squared, Inc.	Dual drive co-rotating spinning scroll compressor or expander
US11530703B2 (en)	2018-07-18	2022-12-20	Air Squared, Inc.	Orbiting scroll device lubrication
US11473572B2 (en)	2019-06-25	2022-10-18	Air Squared, Inc.	Aftercooler for cooling compressed working fluid
US11898557B2 (en)	2020-11-30	2024-02-13	Air Squared, Inc.	Liquid cooling of a scroll type compressor with liquid supply through the crankshaft
US11885328B2 (en)	2021-07-19	2024-01-30	Air Squared, Inc.	Scroll device with an integrated cooling loop

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4001420A (en) *	1968-12-12	1977-01-04	Science Union Et Cie, Societe Francaise De Recherche Medical	Thiazolyl benzoic acid compounds
GB1308028A (en) *	1970-06-12	1973-02-21	Science Union & Cie	Thiazolylbenzoic acid derivatives and a process for their manufactur
JPS4932853A (fr)	1972-07-27	1974-03-26
US4043973A (en)	1974-10-02	1977-08-23	Eastman Kodak Company	Multichromophoric ultraviolet stabilizers for organic compositions
US3939115A (en) *	1974-10-02	1976-02-17	Eastman Kodak Company	Polychromophoric ultraviolet stabilizers and their use in organic compositions
US4164480A (en)	1978-01-09	1979-08-14	Eastman Kodak Company	Polychromophoric ultraviolet stabilizers and their use in organic compositions
SU1078859A1 (ru)	1982-03-31	1997-10-20	Б.М. Красовицкий	2-(5-фенилоксазолил-2)-5-(5-арилоксазолил-2)-бензойные кислоты в качестве органических люминофоров сине-зеленого свечения в органических растворителях и водной среде
JPH0725754B2 (ja)	1986-01-30	1995-03-22	富山化学工業株式会社	新規なチアゾール化合物またはその塩
JP2524786B2 (ja) *	1987-12-15	1996-08-14	コニカ株式会社	直接ポジハロゲン化銀カラ―写真感光材料
DE3903993A1 (de)	1989-02-10	1990-08-16	Basf Ag	Diarylsubstituierte heterocyclische verbindungen, ihre herstellung und arzneimittel daraus
JP2941937B2 (ja)	1990-01-25	1999-08-30	キヤノン株式会社	新規化合物、これを含む液晶組成物及びこれを使用した液晶素子並びに表示装置
JPH04154773A (ja) *	1990-10-15	1992-05-27	Green Cross Corp:The	チアゾール誘導体
ES2173683T3 (es) *	1990-11-30	2002-10-16	Otsuka Pharma Co Ltd	Inhibidor del radical superoxido.
JP3385387B2 (ja) *	1992-05-29	2003-03-10	大塚製薬株式会社	チアゾール誘導体
US5639770A (en)	1992-05-29	1997-06-17	Otsuka Pharmaceutical Co., Ltd.	Thiazole derivatives
US5342851A (en)	1992-10-07	1994-08-30	Mcneil-Ppc, Inc.	Substituted thiazole derivatives useful as platelet aggregation inhibitors
DE4302051A1 (de) *	1993-01-26	1994-07-28	Thomae Gmbh Dr K	5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
TR199700844T1 (xx)	1995-02-24	1998-01-21	Basf Aktiengesellschaft	Pirazolil-Benzoil T�revleri.
JP3964478B2 (ja)	1995-06-30	2007-08-22	エーザイ・アール・アンド・ディー・マネジメント株式会社	ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
JP3865829B2 (ja) *	1995-09-21	2007-01-10	株式会社医薬分子設計研究所	レチノイド作用増強性化合物
ES2124167B1 (es)	1996-06-04	1999-09-16	Espanola Prod Quimicos	Nuevos derivados del bencimidazol con actividad antihistaminica.
WO1998008830A1 (fr) *	1996-08-26	1998-03-05	Byk Gulden Lomberg Chemische Fabrik Gmbh	Nouveaux derives de thiazol s'utilisant comme inhibiteurs selectifs de la pde-iv
JP4300373B2 (ja) *	1996-09-30	2009-07-22	大塚製薬株式会社	サイトカイン産生抑制剤及び接着抑制剤
AUPO691897A0 (en) *	1997-05-21	1997-06-12	Fujisawa Pharmaceutical Co., Ltd.	New compound

1999
- 1999-06-30 CN CN99810103A patent/CN1314899A/zh active Pending
- 1999-06-30 US US09/720,644 patent/US6545009B1/en not_active Expired - Fee Related
- 1999-06-30 EP EP99926853A patent/EP1092711A4/fr not_active Withdrawn
- 1999-06-30 KR KR1020007014995A patent/KR20010053282A/ko not_active Withdrawn
- 1999-06-30 CA CA002332178A patent/CA2332178A1/fr not_active Abandoned
- 1999-06-30 HU HU0102470A patent/HUP0102470A3/hu unknown
- 1999-06-30 PL PL99345247A patent/PL345247A1/xx not_active Application Discontinuation
- 1999-06-30 BR BR9911752-5A patent/BR9911752A/pt not_active Application Discontinuation
- 1999-06-30 ID IDW20010004D patent/ID29247A/id unknown
- 1999-06-30 SK SK2018-2000A patent/SK20182000A3/sk unknown
- 1999-06-30 WO PCT/JP1999/003520 patent/WO2000001679A1/fr not_active Application Discontinuation
- 1999-06-30 IL IL14042299A patent/IL140422A0/xx unknown
- 1999-06-30 AU AU43947/99A patent/AU4394799A/en not_active Abandoned
2000
- 2000-12-19 ZA ZA200007635A patent/ZA200007635B/en unknown
- 2000-12-27 NO NO20006667A patent/NO20006667L/no not_active Application Discontinuation
- 2000-12-28 LV LVP-00-177A patent/LV12633B/en unknown

Also Published As

Publication number	Publication date
EP1092711A4 (fr)	2002-07-31
KR20010053282A (ko)	2001-06-25
LV12633A (lv)	2001-03-20
ID29247A (id)	2001-08-16
PL345247A1 (en)	2001-12-03
NO20006667D0 (no)	2000-12-27
SK20182000A3 (sk)	2001-08-06
AU4394799A (en)	2000-01-24
US6545009B1 (en)	2003-04-08
WO2000001679A1 (fr)	2000-01-13
HUP0102470A3 (en)	2002-05-28
CA2332178A1 (fr)	2000-01-13
LV12633B (en)	2001-07-20
EP1092711A1 (fr)	2001-04-18
CN1314899A (zh)	2001-09-26
ZA200007635B (en)	2002-01-02
HUP0102470A2 (hu)	2002-04-29
IL140422A0 (en)	2002-02-10
BR9911752A (pt)	2001-04-03

Legal Events

Date	Code	Title	Description
2003-02-17	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20006667L (no)	2001-02-28	Retinoid-relaterte reseptor funksjonsregulerende middel
Sun et al.	2018	Methyl-containing pharmaceuticals: Methylation in drug design
Tasaka et al.	2001	Synthesis and structure–activity analysis of novel dihydropyridine derivatives to overcome multidrug resistance
Ishikawa et al.	2009	Discovery of novel 2-(pyridine-2-yl)-1H-benzimidazole derivatives as potent glucokinase activators
ATE303387T1 (de)	2005-09-15	Kondensierte imidazolderivate und arzneimittel gegen diabetes mellitus
Huang et al.	2009	Searching for new cures for tuberculosis: design, synthesis, and biological evaluation of 2-methylbenzothiazoles
TNSN06315A1 (en)	2007-12-03	Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes
Pathak et al.	2014	Synthesis and biological evaluation of substituted 4, 6-diarylpyrimidines and 3, 5-diphenyl-4, 5-dihydro-1H-pyrazoles as anti-tubercular agents
Chen et al.	2007	Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment
MA30476B1 (fr)	2009-06-01	Derives de type cyclohexylpyrazole-lactame comme inhibiteurs de la 11-beta-hydroxysteroïde deshydrogenase de type 1
IL186566A0 (en)	2008-01-20	Substituted 2-amin0alkylth10-benzimidaz0les and use thereof for reducing blood sugar levels
MXPA05011592A (es)	2005-12-15	Compuestos para el tratamiento de trastornos metabolicos.
Hazra et al.	2021	Rhodium-Catalyzed C4-Selective C–H Alkenylation of 2-Pyridones by Traceless Directing Group Strategy
CA2701853A1 (fr)	2009-04-16	Modulateurs des recepteurs metabotropes du glutamate pour le traitement de la maladie de parkinson
Bennett et al.	2012	Fused tricyclic mGluR1 antagonists for the treatment of neuropathic pain
Pati et al.	2020	Synthesis of functionalized arylacetamido-2-pyridones through ortho-C (sp2)–H-activated installation of olefins and alkynes
Suryadevara et al.	2013	Dialkylimidazole inhibitors of Trypanosoma cruzi sterol 14α-demethylase as anti-Chagas disease agents
Pathare et al.	2016	Application of Isocyanides as Amide Surrogates in the Synthesis of Diverse Isoindolin‐1‐one Derivatives by a Palladium‐Catalyzed Tandem Carboxamidation/Hydroamidation Reaction
EP1914229A4 (fr)	2009-03-18	Nouveau dérivé de cercosporamide
UA88772C2 (ru)	2009-11-25	Соединения для лечения расстройств метаболизма
Hwang et al.	2023	Metabolism-guided selective androgen receptor antagonists: design, synthesis, and biological evaluation for activity against enzalutamide-resistant prostate cancer
NO20051901L (no)	2005-04-19	Nye antimycobakterielle sammensetninger og pyrrole derivater som antimycobakterielle sammensetninger
El-Gamil et al.	2022	Development of novel conformationally restricted selective Clk1/4 inhibitors through creating an intramolecular hydrogen bond involving an imide linker
DE602005008282D1 (de)	2008-08-28	Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
SI1656139T1 (sl)	2011-12-30	Aril dikarboksamidi